ChemBK
  • Home
  • Product Category
  • CHN
  1. Home
  2. CAS 947687-13-0
  3. Supplier List
  4. MedChemExpress (MCE)
  5. Inhibitory Antibodies
  6. Ramucirumab (anti-VEGFR)

Request for quotation








Supplier Contact

Supplier NameMedChemExpress (MCE)
Contactsales
Tel609-228-6898
Mobile609-228-6898
QQ
Emailsales@medchemexpress.com; tech@medchemexpress.com
Websitehttps://www.medchemexpress.com/
Wechat
Product NameRamucirumab
SynonymsRamucirumab
CAS947687-13-0
EINECS
Chemical FormulaC285H434N74O88S2
Molecular Weight6369.07
inchi
Package1 mg;5 mg
PriceEmail to quote
DescriptionsRamucirumab (anti-VEGFR)

Ramucirumab (anti-VEGFR)

MedChemExpress (MCE)

HY-P9920A

947687-13-0

99.36%

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping with dry ice.

Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor.

Ramucirumab (10 μg/mL) impedes both VEGF- and tumor-driven cord formation[3]. Ramucirumab does not cross react with mouse VEGFR2[3].

Human

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

| | | |

| | | | | |



[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar

Descriptions

Ramucirumab (anti-VEGFR)

Ramucirumab (anti-VEGFR)

MedChemExpress (MCE)

HY-P9920A

947687-13-0

99.36%

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping with dry ice.

Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor.

Ramucirumab (10 μg/mL) impedes both VEGF- and tumor-driven cord formation[3]. Ramucirumab does not cross react with mouse VEGFR2[3].

Human

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

| | | |

| | | | | |



[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar
8(Spec Feature):49-53. [Content Brief]

[2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb
6(1):71-5. [Content Brief]

[3]. Lowery CD, et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget. 2019 Sep 17
10(53):5523-5533. [Content Brief]

Last Update2025-04-01 14:45:47
MedChemExpress (MCE) also provides

Depatuxizumab

Category: Inhibitory Antibodies
CAS: 1471999-69-5
Last Update: 2025-04-01 14:45:47

Raxibacumab

Category: Inhibitory Antibodies
CAS: 565451-13-0
Last Update: 2025-04-01 14:45:47

Crizanlizumab

Category: Inhibitory Antibodies
CAS: 1690318-25-2
Last Update: 2025-04-01 14:45:47

Sofituzumab vedotin

Category: Inhibitory Antibodies
CAS: 1418200-58-4
Last Update: 2025-04-01 14:45:47

Fazpilodemab

Category: Inhibitory Antibodies
CAS: 2517935-02-1
Last Update: 2025-04-01 14:45:47

Osemitamab

Category: Inhibitory Antibodies
CAS: 2460539-61-9
Last Update: 2025-04-01 14:45:47

Visugromab

Category: Inhibitory Antibodies
CAS: 2556646-63-8
Last Update: 2025-04-01 14:45:47

Vobramitamab

Category: Inhibitory Antibodies
CAS: 2490556-50-6
Last Update: 2025-04-01 14:45:47
  • Home
  • Product Category

© 2015 ChemBK.com All Rights Reserved | Build: 20150530002